Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

AbbVie Inc. researches and develops pharmaceutical products. The Company produces pharmaceutical drugs for specialty therapeutic areas such as immunology, chronic kidney disease, hepatitis C, women"s health, oncology, and neuroscience. AbbVie also offers treatments for diseases including multiple sclerosis, parkinson"s, and alzheimer"s disease.
Website: abbvie.com


  • Good financial results growth rate 14.1% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (-7.9%)
  • Dividend yield for the last twelve months 3.0%
  • Free cash flow yield -1.7% (LTM)
  • Share price is 66.5% higher than minimum and -0.2% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (38.8x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $11.0 mln (-0.003% of cap.)

Key Financials (Download financials)

Ticker: ABBV
Share price, USD:  (+2.0%)220.66
year average price 190.53  


year start price 192.94 2024-09-18

min close price 164.99 2024-11-15

max close price 220.22 2025-09-11

current price 220.66 2025-09-17
Common stocks: 1 768 480 508

Dividend Yield:  3.0%
FCF Yield LTM: -1.7%
EV / LTM EBITDA: 38.8x
EV / EBITDA annualized: 22.0x
Last revenue growth (y/y):  +6.6%
Last growth of EBITDA (y/y):  +21.5%
Historical revenue growth:  +0.7%
Historical growth of EBITDA:  -16.5%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 390 233
Net Debt ($m): 64 059
EV (Enterprise Value): 454 292
EBITDA LTM ($m): 11 713
EV / LTM EBITDA: 38.8x
Price to Book: 63.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-09-13fool.com

3 No-Brainer Dividend Stocks to Buy in September

2025-09-12fool.com

1 Green Flag for AbbVie (ABBV) Stock Right Now

2025-09-12fool.com

The Best Stocks to Invest $50,000 In Right Now

2025-09-11proactiveinvestors.com

AbbVie shares rise with extension of RINVOQ patent protection to 2037

2025-09-11wsj.com

AbbVie in Settlement With Generic Drugmakers on Rinvoq

2025-09-11forbes.com

AbbVie: What's Happening With ABBV Stock?

2025-09-09seekingalpha.com

AbbVie Inc. (ABBV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

2025-09-08zacks.com

This 3 Stock Portfolio Provides Monthly Income

2025-09-08zacks.com

AbbVie (ABBV) Stock Dips While Market Gains: Key Facts

2025-09-08zacks.com

J&J vs. AbbVie: Which Healthcare Powerhouse Is Better Positioned?
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data